SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-24-061626
Filing Date
2024-05-17
Accepted
2024-05-17 16:05:37
Documents
15
Period of Report
2024-06-20

Document Format Files

Seq Description Document Type Size
1 DEF 14A ktra-20240517.htm   iXBRL DEF 14A 828866
2 GRAPHIC img140588224_0.jpg GRAPHIC 73471
3 GRAPHIC img140588224_1.jpg GRAPHIC 74338
4 GRAPHIC img140588224_2.jpg GRAPHIC 256276
5 GRAPHIC img140588224_3.jpg GRAPHIC 323512
  Complete submission text file 0000950170-24-061626.txt   3257250

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ktra-20240517.xsd EX-101.SCH 37097
18 EXTRACTED XBRL INSTANCE DOCUMENT ktra-20240517_htm.xml XML 217506
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 150 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 150 SAN DIEGO CA 92121 (858) 350-4364
Kintara Therapeutics, Inc. (Filer) CIK: 0001498382 (see all company filings)

IRS No.: 990360497 | State of Incorp.: NV | Fiscal Year End: 0630
Type: DEF 14A | Act: 34 | File No.: 001-37823 | Film No.: 24959567
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)